AmCad BioMed Corporation of Taipei City at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

AmCad BioMed Corporation

Fl. 5, No. 167, Fu Hsing N. Rd., 105 Taipei City
Telephone +886 2 27136227
Fax +886 2 25140245

This company is co-exhibitor of
Kaigo Co., Ltd.

Hall map

MEDICA 2018 hall map (Hall 17): stand A62

Fairground map

MEDICA 2018 fairground map: Hall 17

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.02  Imaging supplies
  • 01.02.04  Ultrasound diagnostic equipment

Ultrasound diagnostic equipment

Our products

Product category: Ultrasound diagnostic equipment

AmCAD-UT® Detection

AmCAD-UT® Detection uses statistical pattern recognition and quantification methods to perform analytical processing of images. The physician may process the image for detection of sonographic characteristics (i.e., hyperechoic foci, echogenicity, texture, margin, anechoic areas, taller than wide, tumor shape, and tumor size) with assistance of AmCAD-UT® Detection. AmCAD-UT® Detection provides more detailed information with quantification and visualization of the sonographic characteristics on thyroid nodule that may assist medical professionals in making their diagnostic decision.

  • FDA 510(k)、CE Mark、TFDA、CFDA Clearance
  • Patent-protected technologies - Tumor contour retrieving method、Quantification and imaging of tumor features、Muti-layer classifier
  • Differentiate between benign and malignant thyroid tumor using proprietary patented algorithms
  • Rapid digital reporting system

More Less

About us

Company details


  • AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in the March of 2015 (Ticker: 4188).
  • AmCad BioMed Corporation is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. The company has successfully developed and commercialized a series of the pioneering, first-in-the-world medical devices.
  • AmCad's strong pipeline includes AmCAD-UT (FDA, CE Mark, TFDA, and CFDA for thyroid nodules analysis), AmCAD-UV (FDA and CE Mark, for classifying pulsatile), AmCAD-US (FDA and CE Mark, for backscattered signals analysis), AmCAD-UO (for obstructive sleep apnea detection), AmCAD-CA (for cytopathology analysis) and iSONO accessory (revolutionizing ultrasound imaging). The state-of-the-art pipeline aims for early detection and diagnosis of various types of cancers, such as thyroid cancers, breast cancers, etc., and diseases, including liver fibrosis and obstructive sleep apnea.
  • AmCad's Blue Ocean Strategy for the CAD systems is to develop its own core-technology platforms by providing high value-added, state-of-the-art medical solutions targeting a wide variety of clinical applications and raising the global competition to a higher level. We are ready to make extensive contribution to the health

More Less